PMID- 10078561
OWN - NLM
STAT- MEDLINE
DCOM- 19990330
LR  - 20221207
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 48
IP  - 3
DP  - 1999 Mar
TI  - Brain-derived neurotrophic factor improves blood glucose control and alleviates 
      fasting hyperglycemia in C57BLKS-Lepr(db)/lepr(db) mice.
PG  - 588-94
AB  - Systemic administration of brain-derived neurotrophic factor (BDNF) decreases 
      nonfasted blood glucose in obese, non-insulin-dependent diabetic 
      C57BLKS-Lepr(db)/lepr(db) (db/db) mice, with a concomitant decrease in body 
      weight. By measuring percent HbA1c in BDNF-treated and pair-fed animals, we show 
      that the effects of BDNF on nonfasted blood glucose levels are not caused by 
      decreased food intake but reflect a significant improvement in blood glucose 
      control. Furthermore, once established, this effect can persist for weeks after 
      cessation of BDNF treatment. Oral glucose tolerance tests were performed to 
      examine the effects of BDNF on blood glucose control in the fasted state and 
      after an oral glucose challenge. BDNF treatment normalized fasting blood glucose 
      from initially hyperglycemic levels and also showed evidence for beneficial, 
      although less marked, effects on the ability to remove exogenous glucose from 
      blood. One means to lower fasting blood glucose is to reduce the glucose output 
      of peripheral tissues that normally play a part in the maintenance of fasting 
      hyperglycemia. Because the liver is the major endogenous source of glucose in 
      blood during fasting, and because hepatic weight and glucose output are increased 
      in type 2 diabetes, we evaluated the effects of BDNF on liver tissue. BDNF 
      reduced the hepatomegaly present in db/db mice, in association with reduced liver 
      glycogen and reduced liver enzyme activity in serum, supporting the possible 
      involvement of liver tissue in the mechanism of action for BDNF.
FAU - Tonra, J R
AU  - Tonra JR
AD  - Regeneron Pharmaceuticals, Tarrytown, New York 10591, USA.
FAU - Ono, M
AU  - Ono M
FAU - Liu, X
AU  - Liu X
FAU - Garcia, K
AU  - Garcia K
FAU - Jackson, C
AU  - Jackson C
FAU - Yancopoulos, G D
AU  - Yancopoulos GD
FAU - Wiegand, S J
AU  - Wiegand SJ
FAU - Wong, V
AU  - Wong V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Blood Glucose)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Liver Glycogen)
SB  - IM
MH  - Animals
MH  - Blood Glucose/drug effects/*metabolism
MH  - Brain-Derived Neurotrophic Factor/*pharmacology/*therapeutic use
MH  - Diabetes Mellitus/blood/drug therapy/*metabolism
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/*metabolism
MH  - Fasting
MH  - Glucose Tolerance Test
MH  - Glycated Hemoglobin/analysis
MH  - Heterozygote
MH  - Hyperglycemia/*prevention & control
MH  - Liver/drug effects/metabolism
MH  - Liver Glycogen/metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Mutant Strains
MH  - *Obesity
MH  - Time Factors
EDAT- 1999/03/17 00:00
MHDA- 1999/03/17 00:01
CRDT- 1999/03/17 00:00
PHST- 1999/03/17 00:00 [pubmed]
PHST- 1999/03/17 00:01 [medline]
PHST- 1999/03/17 00:00 [entrez]
AID - 10.2337/diabetes.48.3.588 [doi]
PST - ppublish
SO  - Diabetes. 1999 Mar;48(3):588-94. doi: 10.2337/diabetes.48.3.588.